Patents by Inventor Jung-Hee Woo
Jung-Hee Woo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10626427Abstract: The present invention relates to a mutated protein of FMO derived from Celeribacter sp. and a gene encoding the same, a vector comprising the gene, a recombinant cell transformed by the vector, a composition for producing indigo comprising them, and a method for increasing indigo production in the recombinant cell using the transformed recombinant cell.Type: GrantFiled: April 22, 2019Date of Patent: April 21, 2020Assignee: GYEONGBUK INSTITUTE FOR MARINE BIOINDUSTRYInventors: Jung Hee Woo, Hae Seon Kim, Nyun-Ho Park
-
Publication number: 20190323047Abstract: The present invention relates to a mutated protein of FMO derived from Celeribacter sp. and a gene encoding the same, a vector comprising the gene, a recombinant cell transformed by the vector, a composition for producing indigo comprising them, and a method for increasing indigo production in the recombinant cell using the transformed recombinant cell.Type: ApplicationFiled: April 22, 2019Publication date: October 24, 2019Inventors: Jung Hee WOO, Hae Seon Kim, Nyun-Ho Park
-
Patent number: 9364557Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: GrantFiled: August 1, 2008Date of Patent: June 14, 2016Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SCOTT AND WHITE HEALTHCAREInventors: David M. Neville, Jr., Jung-Hee Woo, Arthur Frankel
-
Patent number: 8987426Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: April 10, 2012Date of Patent: March 24, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 8921097Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: GrantFiled: November 30, 2010Date of Patent: December 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20130217861Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: ApplicationFiled: November 30, 2010Publication date: August 22, 2013Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David M. Neville, JR., Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20130211049Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: April 10, 2012Publication date: August 15, 2013Applicants: Office of Technology TransferInventors: David M. Neville, JR., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20120232010Abstract: The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.Type: ApplicationFiled: October 14, 2010Publication date: September 13, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: Thomas Flaig, Arthur E. Frankel, Andrew Thorburn, L.Michael Glode, Jung Hee Woo, David Neville
-
Patent number: 8217158Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: March 5, 2010Date of Patent: July 10, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 8030048Abstract: The present invention relates to enantioselective epoxide hydrolase proteins isolated from marine microorganisms, which has high enantioselectivity to various epoxide substrates, and a method of preparing the epoxides with high enantio-purity by using the epoxide hydrolases. The enantioselective hydrolase protein of the present invention can be applied for the preparation of enantiopure epoxides with high bioactivity at a high yield.Type: GrantFiled: October 4, 2006Date of Patent: October 4, 2011Assignee: Korea Ocean Research and Development InstituteInventors: Sang-Jin Kim, Sung-Gyun Kang, Young-Ok Hwang, Jung-Hee Woo, Jang-Cheon Cho, Ji-Hyun Kang, Kae-Kyoung Kwon
-
Publication number: 20110189209Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: ApplicationFiled: August 1, 2008Publication date: August 4, 2011Applicant: The Government of The United States of America as Represented by the Secretary, Dept. of HealthInventors: David M. Neville, JR., Jung-Hee Woo, Arthur Frankel
-
Publication number: 20110086416Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: March 5, 2010Publication date: April 14, 2011Applicant: The Government of the US, as Represented by the Secretary, Department of Health and Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 7892786Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: GrantFiled: August 2, 2004Date of Patent: February 22, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20100120102Abstract: The present invention relates to enantioselective epoxide hydrolase proteins isolated from marine microorganisms, which has high enantioselectivity to various epoxide substrates, and a method of preparing the epoxides with high enantio-purity by using the epoxide hydrolases. The enantioselective hydrolase protein of the present invention can be applied for the preparation of enantiopure epoxides with high bioactivity at a high yield.Type: ApplicationFiled: October 4, 2006Publication date: May 13, 2010Applicant: Korea Ocean Research and Development InstituteInventors: Sang-Jin Kim, Sung-Gyun Kang, Young-Ok Hwang, Jung-Hee Woo, Jang-Cheon Cho, Ji-Hyun Kang, Kae-Kyoung Kwon
-
Patent number: 7696338Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.Type: GrantFiled: May 18, 2001Date of Patent: April 13, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20060216782Abstract: In one aspect the present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaing a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/10 L of initial volume during induction along with a continuous inusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: ApplicationFiled: August 2, 2004Publication date: September 28, 2006Inventors: David Neville, Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20060094083Abstract: The present invention relates to probiotic microorganisms producing chimeric human growth hormone for oral use and methods for preparing them. The invention provides probiotic Lactobacillus or yeast transformant expressing chimeric protein which is human growth hormone fused with Fc fragment of human IgG, in which the transformants are safely delivered into intestine though oral route. Also, the invention provides a chimeric protein-expressing vector which can induce transcytosis in intestine epithelial cells. Accordingly, the invention demonstrates that the chimeric protein for oral delivery system can be absorbed in intestine, and delivery of the chimeric protein by oral route using Lactobacillus has very excellent efficiency in vivo test in rats. Accordingly, the Lactobacillus of the present invention is an excellent deliverer of protein drugs.Type: ApplicationFiled: August 26, 2005Publication date: May 4, 2006Inventors: Yun-Jaie Choi, Chang-Hoon Lee, Jung-Hee Woo, Seung-Ha Kang, Seung-Hoon Choi, Sang-Kee Kang
-
Publication number: 20040127682Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: January 13, 2004Publication date: July 1, 2004Inventors: David M Neville, Jerry T Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan